Quick Answer
Matinas BioPharma Holdings, Inc. reported Net Income Loss of -$10.35 million for the year ending 2025.
- Matinas BioPharma Holdings, Inc. showed an increase of +57.3% in Net Income Loss from 2024 to 2025.
- This data is from Matinas BioPharma Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: -$343.3 thousand | Q3 2013: -$1.46 million | Q1 2014: -$2.14 million | Q2 2014: -$2.43 million | Q3 2014: -$2.61 million | Q1 2015: -$2.57 million | Q2 2015: -$2.40 million | Q3 2015: -$2.15 million | Q1 2016: -$2.24 million | Q2 2016: -$1.62 million | Q3 2016: -$1.84 million | Q1 2017: -$4.50 million | Q2 2017: -$3.97 million | Q3 2017: -$3.39 million | Q1 2018: -$4.11 million | Q2 2018: -$3.41 million | Q3 2018: -$2.94 million | Q1 2019: -$4.05 million | Q2 2019: -$3.34 million | Q3 2019: -$4.40 million | Q1 2020: -$5.05 million | Q2 2020: -$5.61 million | Q3 2020: -$5.45 million | Q1 2021: -$4.96 million | Q2 2021: -$4.79 million | Q3 2021: -$6.84 million | Q1 2022: -$5.98 million | Q2 2022: -$5.92 million | Q3 2022: -$5.46 million | Q1 2023: -$5.51 million | Q2 2023: -$6.06 million | Q3 2023: -$6.06 million | Q1 2024: -$5.82 million | Q2 2024: -$5.72 million | Q3 2024: -$4.28 million | Q1 2025: -$1.66 million | Q2 2025: -$5.25 million | Q3 2025: -$1.53 million.
- Over the full 13 years of available data (2013 to 2025), Matinas BioPharma Holdings, Inc.'s Net Income Loss has declined by 178.6%.
- Historical annual values: Fiscal year 2025: -$10.35 million | Fiscal year 2024: -$24.25 million | Fiscal year 2023: -$22.94 million | Fiscal year 2022: -$21.00 million | Fiscal year 2021: -$23.28 million | Fiscal year 2020: -$22.45 million | Fiscal year 2019: -$17.37 million | Fiscal year 2018: -$14.08 million | Fiscal year 2017: -$15.49 million | Fiscal year 2016: -$7.60 million | Fiscal year 2015: -$9.14 million | Fiscal year 2014: -$10.22 million | Fiscal year 2013: -$3.71 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: